<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="a7c01089-85f5-40aa-b679-f53a425b4d68"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use DEXRAZOXANE FOR INJECTION safely and effectively. See full prescribing information for DEXRAZOXANE FOR INJECTION. <br/> DEXRAZOXANE for injection <br/>  Initial U.S. Approval: 1995<br/>
   </title>
   <effectiveTime value="20250409"/>
   <setId root="a7c01089-85f5-40aa-b679-f53a425b4d68"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="081109687"/>
            <name>Novadoz Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650786952" root="1.3.6.1.4.1.519.1"/>
                        <name>MSN LABORATORIES  PRIVATE LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72205-247" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72205-248" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72205-247" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72205-248" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e9539f3e-7465-4cd9-89c4-9632bfe72782"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250409"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72205-247" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dexrazoxane<suffix/>
                        </name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dexrazoxane</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="250" unit="mg"/>
                              <denominator value="25" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5346058Q7S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXRAZOXANE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="048L81261F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXRAZOXANE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="25" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72205-247-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250409"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216748" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <effectiveTime>
                              <low value="20250326"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250326"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72205-248" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dexrazoxane<suffix/>
                        </name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dexrazoxane</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="50" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5346058Q7S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXRAZOXANE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="048L81261F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXRAZOXANE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72205-248-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250409"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216748" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <effectiveTime>
                              <low value="20250326"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250326"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="c7498491-7943-487c-be2c-633fd6de9f34"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy <content styleCode="italics">[see <linkHtml href="#Section_5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250409"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation. (<linkHtml href="#Section_1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="dc87d0f9-a3f3-42bf-8276-1e2341a10ee3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250409"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Reconstitute vial contents and dilute before use. (<linkHtml href="#Section_2.3">2.3</linkHtml>)</item>
                           <item>Administer dexrazoxane for injection by intravenous infusion over 15 minutes.</item>
                           <item>DO NOT ADMINISTER VIA AN INTRAVENOUS PUSH. (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_2.3">2.3</linkHtml>)</item>
                           <item>The recommended dosage ratio of dexrazoxane for injection to doxorubicin is 10:1 (e.g., 500 mg/m<sup>2</sup> dexrazoxane for injection to 50 mg/m<sup>2</sup> doxorubicin). Do not administer doxorubicin before dexrazoxane for injection. (<linkHtml href="#Section_2.1">2.1</linkHtml>)</item>
                           <item>Reduce dose by 50% for patients with creatinine clearance &lt;40 mL/min. (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_8.7">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="989d50d8-10b6-464f-bb51-9adbe606e548"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1	Recommended Dose</title>
                     <text>
                        <paragraph>Administer dexrazoxane for injection via intravenous infusion over 15 minutes. DO NOT ADMINISTER VIA AN INTRAVENOUS PUSH.<br/> The recommended dosage ratio of dexrazoxane for injection to doxorubicin is 10:1 (e.g., 500 mg/m<sup>2</sup> dexrazoxane for injection to 50 mg/m<sup>2</sup> doxorubicin). Do not administer doxorubicin before dexrazoxane for injection. Administer doxorubicin within 30 minutes after the completion of dexrazoxane for injection infusion.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="e896fb96-f5ce-4e9f-bc59-b50d759c539b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2	Dose Modifications</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Dosing in Patients with Renal Impairment</content>
                           <br/> Reduce dexrazoxane for injection dosage in patients with moderate to severe renal impairment (creatinine clearance values less than 40 mL/min) by 50% (Dexrazoxane for injection to doxorubicin ratio reduced to 5:1; such as 250 mg/m<sup>2</sup> dexrazoxane for injection to 50 mg/m<sup>2</sup> doxorubicin) <content styleCode="italics">[see <linkHtml href="#Section_8.6">Use in Specific Populations (8.6)</linkHtml> and <linkHtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                           <br/>
                           <content styleCode="italics">Dosing in Patients with Hepatic Impairment</content>
                           <br/> Since a doxorubicin dose reduction is recommended in the presence of hyperbilirubinemia, reduce the dexrazoxane for injection dosage proportionately (maintaining the 10:1 ratio) in patients with hepatic impairment.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="75433078-0ec3-4028-a792-dda9859985e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3	Preparation and Administration</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Preparation and Handling of Infusion Solution</content>
                           <br/> Reconstitute dexrazoxane for injection with Sterile Water for Injection, USP. Reconstitute with 25 mL for a dexrazoxane for injection 250 mg vial and 50 mL for a dexrazoxane for injection 500 mg vial to give a concentration of 10 mg/mL. Dilute the reconstituted solution further with Lactated Ringer’s Injection, USP to a concentration of 1.3 to 3.0 mg/mL in intravenous infusion bags for intravenous infusion.<br/> Following reconstitution with Sterile Water for Injection, USP, dexrazoxane for injection is stable for 30 minutes at room temperature or if storage is necessary, up to 3 hours from the time of reconstitution when stored under refrigeration, 2° to 8°C (36° to 46°F). The pH of the resultant solution is 1.0 to 3.0. DISCARD UNUSED SOLUTIONS. The diluted infusion solutions are stable for one hour at room temperature or if storage is necessary, up to 4 hours when stored under refrigeration, 2° to 8°C (36° to 46°F). The infusion solutions have a pH of 3.5 to 5.5. DISCARD UNUSED SOLUTIONS.<br/> Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions containing a precipitate should be discarded.<br/> Use caution when handling and preparing the reconstituted solution. The use of gloves is recommended. If dexrazoxane for injection powder or solutions contact the skin or mucosae, wash exposed area immediately and thoroughly with soap and water. Follow special handling and disposal procedures.<sup>1</sup>
                           <br/>
                           <content styleCode="italics">Administration</content>
                           <br/> Do not mix dexrazoxane for injection with other drugs.<br/> Administer the final diluted solution of dexrazoxane for injection by intravenous infusion over 15 minutes before the administration of doxorubicin. DO NOT ADMINISTER VIA AN INTRAVENOUS PUSH. Administer doxorubicin within 30 minutes after the completion of dexrazoxane for injection infusion.</paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="33cf4626-2fc1-4a21-8503-5334b15a6935"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>For injection: 250 mg or 500 mg of dexrazoxane as a sterile, off white to pale yellow lyophilized powder in a single-dose vials for reconstitution.</paragraph>
               </text>
               <effectiveTime value="20250409"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 250 mg or 500 mg of dexrazoxane as a sterile, lyophilized powder in a single-dose vials for reconstitution. (<linkHtml href="#Section_3">3</linkHtml>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="302b8a5d-b728-4f27-9041-f91fa7c7fee8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Do not use dexrazoxane with non-anthracycline chemotherapy regimens.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250409"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dexrazoxane should not be used with non-anthracycline chemotherapy regimens. (<linkHtml href="#Section_4">4</linkHtml>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="b272958e-2d99-44de-b654-42f24dbf58fd"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250409"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Myelosuppression: Dexrazoxane may increase the myelosuppresive effects of chemotherapeutic agents. Perform hematological monitoring. (<linkHtml href="#Section_5.1">5.1</linkHtml>)</item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. Advise female patients of reproductive potential of the potential hazard to the fetus. (<linkHtml href="#Section_5.5">5.5</linkHtml>, <linkHtml href="#Section_8.1">8.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="41beb7ee-bd98-45c0-878e-69155b566214"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1	Myelosuppression</title>
                     <text>
                        <paragraph>Dexrazoxane may add to the myelosuppression caused by chemotherapeutic agents. Obtain a complete blood count prior to and during each course of therapy, and administer dexrazoxane and chemotherapy only when adequate hematologic parameters are met.</paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="445ffdf7-eefb-4363-82a0-bd815fb140c5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2	Concomitant Chemotherapy</title>
                     <text>
                        <paragraph>Only use dexrazoxane in those patients who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> and are continuing with doxorubicin therapy. Do not use with chemotherapy initiation as dexrazoxane may interfere with the antitumor activity of the chemotherapy regimen. In a trial conducted in patients with metastatic breast cancer who were treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC) with or without dexrazoxane starting with their first cycle of FAC therapy, patients who were randomized to receive dexrazoxane had a lower response rate (48% vs. 63%) and shorter time to progression than patients who were randomized to receive placebo.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="5736f574-724a-4e75-b21a-6a6fab77b5ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3	Cardiac Toxicity</title>
                     <text>
                        <paragraph>Treatment with dexrazoxane does not completely eliminate the risk of anthracycline-induced cardiac toxicity. Monitor cardiac function before and periodically during therapy to assess left ventricular ejection fraction (LVEF). In general, if test results indicate deterioration in cardiac function associated with doxorubicin, the benefit of continued therapy should be carefully evaluated against the risk of producing irreversible cardiac damage.</paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="4545dbb2-85df-49bf-99a8-79f9884963a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4	Secondary Malignancies</title>
                     <text>
                        <paragraph>Secondary malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in studies of pediatric patients who have received dexrazoxane in combination with chemotherapy. Dexrazoxane is not indicated for use in pediatric patients. Some adult patients who received dexrazoxane in combination with anti-cancer agents known to be carcinogenic have also developed secondary malignancies, including AML and MDS.<br/> Razoxane is the racemic mixture, of which dexrazoxane is the S(+)-enantiomer. Secondary malignancies (primarily acute myeloid leukemia) have been reported in patients treated chronically with oral razoxane. In these patients, the total cumulative dose of razoxane ranged from 26 to 480 grams and the duration of treatment was from 42 to 319 weeks. One case of T-cell lymphoma, one case of B-cell lymphoma, and six to eight cases of cutaneous basal cell or squamous cell carcinoma have also been reported in patients treated with razoxane. Long-term administration of razoxane to rodents was associated with the development of malignancies<content styleCode="italics"> [see <linkHtml href="#Section_13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="a857b66c-db52-4a70-8d5a-c6894f3c9390"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5	Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Dexrazoxane can cause fetal harm when administered to pregnant women. Dexrazoxane administration during the period of organogenesis resulted in maternal toxicity, embryotoxicity and teratogenicity in rats and rabbits at doses significantly lower than the clinically recommended dose <content styleCode="italics">[see <linkHtml href="#Section_8.1">Use in Specific Populations (8.1)</linkHtml>].</content> If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.<br/> Advise female patients of reproductive potential to avoid becoming pregnant and to use highly effective contraception during treatment <content styleCode="italics">[see <linkHtml href="#Section_8.6">Use in Specific Populations (8.6)</linkHtml>].</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="8a91a1d1-eee9-449d-b0a2-deefb7be6bde"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250409"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>In clinical studies, dexrazoxane was administered to patients also receiving chemotherapeutic agents for cancer. Pain on injection was observed more frequently in patients receiving dexrazoxane versus placebo. (<linkHtml href="#Section_6.1">6.1</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="26e2ff81-785b-4ee0-9429-45c5f0c7977c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.<br/> The adverse reaction profile described in this section was identified from randomized, placebo- controlled, double-blind studies in patients with metastatic breast cancer who received the combination of the FAC chemotherapy regimen with or without dexrazoxane. The dose of doxorubicin was 50 mg/m<sup>2</sup> in each of these trials. Treatment was administered every three weeks until disease progression or cardiac toxicity.<br/> Patients in clinical trials who received FAC with dexrazoxane experienced more severe leukopenia, granulocytopenia, and thrombocytopenia than patients receiving FAC without dexrazoxane <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                           <br/> Table 1 below lists the incidence of adverse reactions for patients receiving FAC with either dexrazoxane or placebo in the breast cancer studies. Adverse experiences occurring during courses 1 through 6 are displayed for patients receiving dexrazoxane or placebo with FAC beginning with their first course of therapy (columns 1 and 3, respectively). Adverse experiences occurring at course 7 and beyond for patients who received placebo with FAC during the first six courses and who then received either dexrazoxane or placebo with FAC are also displayed (columns 2 and 4, respectively).<br/> The adverse reactions listed below in Table 1 demonstrate that the frequency of adverse reaction “Pain on Injection” has been greater for dexrazoxane arm, as compared to placebo.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1<br/>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <colgroup>
                              <col width="22.3%"/>
                              <col width="19.42%"/>
                              <col width="19.42%"/>
                              <col width="19.42%"/>
                              <col width="19.44%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" rowspan="3"> Adverse Reaction<br/> </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="4" align="center"> Percentage (%) of Breast Cancer Patients With Adverse Reaction<br/> </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center"> FAC + Dexrazoxane<br/> </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center"> FAC + Placebo<br/> </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center"> Courses 1-6<br/> N = 413<br/> </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center"> Courses ≥ 7<br/> N = 102<br/> </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center"> Courses 1-6<br/> N = 458<br/> </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center"> Courses ≥ 7<br/> N = 99<br/> </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Alopecia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 94<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 100<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 97<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 98<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Nausea<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 77<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 51<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 84<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 60<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Vomiting<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 59<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 42<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 72<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 49<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Fatigue/Malaise<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 61<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 48<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 58<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 55<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Anorexia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 42<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 27<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 47<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 38<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Stomatitis<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 34<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 26<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 41<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 28<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Fever<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 34<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 22<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 29<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 18<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Infection<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 23<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 19<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 18<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 21<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Diarrhea<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 21<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 14<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 24<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 7<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Pain on Injection<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 13<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Sepsis<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 17<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 14<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 9<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Neurotoxicity<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 17<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 10<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 13<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Streaking/Erythema<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 4<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 4<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Phlebitis<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Esophagitis<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 4<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Dysphagia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 10<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Hemorrhage<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Extravasation<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Urticaria<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Recall Skin<br/> Reaction<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="9c11e596-603e-4715-8bac-297f05a16413"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>No drug interactions have been identified <content styleCode="italics">[see <linkHtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250409"/>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="52f896ab-d882-4002-aa56-5bd616949fe4"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250409"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Nursing Mothers: Discontinue drug or nursing. (<linkHtml href="#Section_8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="ebac4780-582a-418d-9357-76f5ed17e391"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>Pregnancy Category D <br/>
                           <content styleCode="italics">Risk Summary</content>
                           <br/> Dexrazoxane can cause fetal harm when administered to pregnant women. Dexrazoxane administration resulted in maternal toxicity, embryotoxicity and teratogenicity in rats and rabbits at doses significantly lower than the clinically recommended dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <content styleCode="italics">[see <linkHtml href="#Section_5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                           <br/>
                           <content styleCode="italics">Animal Data</content>
                           <br/> Dexrazoxane resulted in maternal toxicity in rats at doses of ≥2 mg/kg (1/40 the human dose on a mg/m<sup>2</sup> basis) and embryotoxicity and teratogenicity at 8 mg/kg (approximately 1/10 the human dose on a mg/m<sup>2</sup> basis) when given daily to pregnant rats during the period of organogenesis. Teratogenic effects in the rat included imperforate anus, microphthalmia, and anophthalmia. In offspring allowed to develop to maturity, fertility was impaired in the male and female rats treated in utero during organogenesis at 8 mg/kg. In rabbits, doses of ≥5 mg/kg (approximately 1/10 the human dose on a mg/m<sup>2</sup> basis) daily during the period of organogenesis caused maternal toxicity and doses of 20 mg/kg (1/2 the human dose on a mg/m<sup>2</sup> basis) were embryotoxic and teratogenic. Teratogenic effects in the rabbit included several skeletal malformations such as short tail, rib and thoracic malformations, and soft tissue variations including subcutaneous, eye and cardiac hemorrhagic areas, as well as agenesis of the gallbladder and of the intermediate lobe of the lung.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="196d657f-825e-40f3-af19-e4a94554b316"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether dexrazoxane or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from dexrazoxane, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="bf60c18e-349d-4d23-ab0a-1b46b5cb14e1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of dexrazoxane in pediatric patients have not been established <content styleCode="italics">[see <linkHtml href="#Section_5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="cc7b3e8c-7d4a-4ec4-9778-6086f7719ba5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of dexrazoxane did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="42d1e6a1-792f-4375-90dc-a0636c786d97"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.6	Females of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Contraception</content>
                           <br/> Dexrazoxane can cause fetal harm when administered during pregnancy. Advise female patients of reproductive potential to use highly effective contraception during treatment <content styleCode="italics">[see <linkHtml href="#Section_8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="a284dcd3-2745-4724-bec6-9a141c445807"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.7	Renal Impairment</title>
                     <text>
                        <paragraph>Greater exposure to dexrazoxane may occur in patients with compromised renal function. Reduce the dexrazoxane dose by 50% in patients with creatinine clearance values &lt;40 mL/min <content styleCode="italics">[see <linkHtml href="#Section_2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="e8097614-9fe2-4905-863b-7b1fe9932d56"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There are no data on overdosage in the cardioprotective trials; the maximum dose administered during the cardioprotective trials was 1000 mg/m<sup>2</sup> every three weeks.<br/> Disposition studies with dexrazoxane have not been conducted in cancer patients undergoing dialysis, but retention of a significant dose fraction (&gt;0.4) of the unchanged drug in the plasma pool, minimal tissue partitioning or binding, and availability of greater than 90% of the systemic drug levels in the unbound form suggest that it could be removed using conventional peritoneal or hemodialysis.<br/> There is no known antidote for dexrazoxane. Instances of suspected overdose should be managed with good supportive care until resolution of myelosuppression and related conditions is complete. Management of overdose should include treatment of infections, fluid regulation, and maintenance of nutritional requirements.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250409"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="bda3aa0c-93e4-49c4-8832-f1076fc06fd3"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Dexrazoxane for injection, a cardioprotective agent for use in conjunction with doxorubicin, is a sterile, pyrogen-free lyophilizate intended for intravenous administration.<br/> Chemically, dexrazoxane is (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione. The structural formula is as follows:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>C<sub>11</sub>H<sub>16</sub>N<sub>4</sub>O<sub>4</sub>    M.W. 268.28</paragraph>
                  <paragraph>Dexrazoxane, an intracellular chelating agent, is a derivative of EDTA. Dexrazoxane is a white to off-white crystalline powder that melts at 191° to 197°C. It is sparingly soluble in 0.1 N HCl, slightly soluble in water, very slightly soluble in methanol, and insoluble in cyclohexane. The pKa is 2.2. Dexrazoxane has an octanol/water partition coefficient of (-) 1.43 and degrades rapidly above a pH of 7.0.<br/> Each 250 mg vial contains dexrazoxane hydrochloride equivalent to 250 mg dexrazoxane. Hydrochloric Acid, NF is added for pH adjustment. When reconstituted as directed with 25 mL of Sterile Water for Injection, USP, each mL contains: 10 mg dexrazoxane. The pH of the resultant solution is 1.0 to 3.0.<br/> Each 500 mg vial contains dexrazoxane hydrochloride equivalent to 500 mg dexrazoxane. Hydrochloric Acid, NF is added for pH adjustment. When reconstituted as directed with 50 mL of Sterile Water for Injection, USP, each mL contains: 10 mg dexrazoxane. The pH of the resultant solution is 1.0 to 3.0.<br/> The reconstituted dexrazoxane for injection, solutions prepared from Sterile Water for Injection, USP, are intended for further dilution with Lactated Ringer’s Injection, USP, for rapid intravenous drip infusion. DO NOT ADMINISTER VIA AN INTRAVENOUS PUSH <content styleCode="italics">[see Dosage and Administration (2.1, 2.3)].</content>
                  </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250409"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>dexra-inj-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dexra-inj-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="154f205b-e3cb-4c13-b7d6-5c4320593ec8"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250409"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="e32cd725-4c82-467a-b168-c175aca49fdd"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism by which dexrazoxane exerts its cytoprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.</paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="b7e45cfe-42c9-4494-aaa2-60ba012a8b5d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of dexrazoxane have been studied in advanced cancer patients with normal renal and hepatic function. The pharmacokinetics of dexrazoxane can be adequately described by a two-compartment open model with first-order elimination. Dexrazoxane has been administered as a 15 minute infusion over a dose range of 60 to 900 mg/m<sup>2</sup> with 60 mg/m<sup>2</sup> of doxorubicin, and at a fixed dose of 500 mg/m<sup>2</sup> with 50 mg/m<sup>2</sup> doxorubicin. The disposition kinetics of dexrazoxane are dose-independent, as shown by linear relationship between the area under plasma concentration-time curves and administered doses ranging from 60 to 900 mg/m<sup>2</sup>. The mean peak plasma concentration of dexrazoxane was 36.5 µg/mL at 15- minute after intravenous administration of 500 mg/m<sup>2</sup> dose of dexrazoxane over 15 to 30 minutes prior to the 50 mg/m<sup>2</sup> doxorubicin dose.<br/> The important pharmacokinetic parameters of dexrazoxane are summarized in Table 2:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: SUMMARY OF MEAN (%CV<sup>a</sup>) DEXRAZOXANE<br/> PHARMACOKINETIC PARAMETERS AT A DOSAGE RATIO OF<br/> 10:1 OF DEXRAZOXANE:DOXORUBICIN</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <colgroup>
                              <col width="14.46%"/>
                              <col width="16.84%"/>
                              <col width="13.68%"/>
                              <col width="13.7%"/>
                              <col width="13.7%"/>
                              <col width="13.7%"/>
                              <col width="13.94%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="top"> Dose<br/> Doxorubicin (mg/m<sup>2</sup>)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Dose<br/> Dexrazoxane (mg/m<sup>2</sup>)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Number of<br/> Subjects<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Elimination<br/> Half-Life (h)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Plasma<br/> Clearance (L/h/m<sup>2</sup>)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Renal<br/> Clearance (L/h/m<sup>2</sup>)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <sup>b</sup>Volume of<br/> Distribution (L/m<sup>2</sup>)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="top"> 50<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 500<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 10<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2.5 (16)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 7.88 (18)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3.35 (36)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 22.4 (22)<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="center" valign="top"> 60<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 600<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2.1 (29)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 6.25 (31)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> —<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 22.0 (55)<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a</sup> Coefficient of variation<br/>
                           <sup>b</sup> Steady-state volume of distribution<br/>
                           <content styleCode="italics">Distribution</content>
                           <br/> Following a rapid distributive phase (0.2 to 0.3 hours), dexrazoxane reaches post-distributive equilibrium within two to four hours. The estimated mean steady-state volume of distribution of dexrazoxane is 22.4 L/m<sup>2</sup> after 500 mg/m<sup>2</sup> of dexrazoxane dose followed by 50 mg/m<sup>2</sup> of doxorubicin, suggesting distribution throughout total body water (25 L/m<sup>2</sup>).<br/>
                           <content styleCode="italics">In vitro</content> studies have shown that dexrazoxane is not bound to plasma proteins.<br/>
                           <content styleCode="italics">Metabolism</content>
                           <br/> Qualitative metabolism studies with dexrazoxane have confirmed the presence of unchanged drug, a diacid-diamide cleavage product, and two monoacid-monoamide ring products in the urine of animals and man. The metabolite levels were not measured in the pharmacokinetic studies.<br/>
                           <content styleCode="italics">Excretion</content>
                           <br/> Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of a 500 mg/m<sup>2</sup> dose of dexrazoxane was excreted in the urine. Renal clearance averages 3.35 L/h/m<sup>2</sup> after the 500 mg/m<sup>2</sup> dexrazoxane dose followed by 50 mg/m<sup>2</sup> of doxorubicin.<br/>
                           <content styleCode="italics">Specific Populations<br/> Pediatric</content>
                           <br/> Pharmacokinetics following dexrazoxane administration have not been evaluated in pediatric patients.<br/>
                           <content styleCode="italics">Effect of Renal Impairment</content>
                           <br/> The pharmacokinetics of dexrazoxane were assessed following a single 15-minute IV infusion of 150 mg/m<sup>2</sup> of dexrazoxane. Dexrazoxane clearance was reduced in subjects with renal dysfunction. Compared with controls, the mean AUC<sub>0-inf</sub> value was two-fold greater in subjects with moderate (CL<sub>CR</sub> 30-50 mL/min) to severe (CL<sub>CR</sub> &lt;30 mL/min) renal dysfunction. Modeling demonstrated that equivalent exposure (AUC<sub>-inf</sub>) could be achieved if dosing were reduced by 50% in subjects with creatinine clearance values &lt;40 mL/min compared with control subjects (CL<sub>CR</sub> &gt;80 mL/min) <content styleCode="italics">[see Use in Specific Populations (8.7) and Dosage and Administration (2.2)].</content>
                           <br/>
                           <content styleCode="italics">Effect of Hepatic Impairment</content>
                           <br/> Pharmacokinetics following dexrazoxane administration have not been evaluated in patients with hepatic impairment. The dexrazoxane dose is dependent upon the dose of doxorubicin <content styleCode="italics">[see Dosage and Administration (2.2)].</content>
                           <br/>
                           <content styleCode="italics">Drug Interactions</content>
                           <br/> There was no significant change in the pharmacokinetics of doxorubicin (50 mg/m<sup>2</sup>) and its predominant metabolite, doxorubicinol, in the presence of dexrazoxane (500 mg/m<sup>2</sup>) in a crossover study in cancer patients.</paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="98847e0b-3f0c-417b-a552-fc08f6ebdb0e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250409"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="d47454ea-531e-4d6b-8c66-d3f932e37495"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No long-term carcinogenicity studies have been carried out with dexrazoxane in animals. Nevertheless, a study by the National Cancer Institute has reported that long-term dosing with razoxane (the racemic mixture of dexrazoxane, ICRF-187, and its enantiomer ICRF-186) is associated with the development of malignancies in rats and possibly in mice <content styleCode="italics">[see Warnings and Precautions (5.4)].</content>
                           <br/> Dexrazoxane was not mutagenic in the bacterial reverse mutation (Ames) test, but was found to be clastogenic to human lymphocytes <content styleCode="italics">in vitro</content> and to mouse bone marrow erythrocytes<content styleCode="italics"> in vivo</content> (micronucleus test).<br/> Dexrazoxane has the potential to impair fertility in male patients based on effects in repeat-dose toxicology studies. Testicular atrophy was seen with dexrazoxane administration at doses as low as 30 mg/kg weekly for 6 weeks in rats (1/3 the human dose on a mg/m<sup>2</sup> basis) and as low as 20 mg/kg weekly for 13 weeks in dogs (approximately equal to the human dose on a mg/m<sup>2</sup> basis).</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="eb613c20-9e5d-4cd9-8c5c-f315982f22f1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The ability of dexrazoxane to prevent/reduce the incidence and severity of doxorubicin-induced cardiomyopathy was evaluated in three prospectively randomized placebo-controlled studies. In these studies, patients were treated with a doxorubicin-containing regimen and either dexrazoxane or placebo starting with the first course of chemotherapy. There was no restriction on the cumulative dose of doxorubicin. Cardiac function was assessed by measurement of the LVEF, utilizing resting multigated nuclear medicine (MUGA) scans, and by clinical evaluations. Patients receiving dexrazoxane had significantly smaller mean decreases from baseline in LVEF and lower incidences of congestive heart failure than the control group; however, in the largest study, patients with advanced breast cancer receiving FAC with dexrazoxane had a lower response rate (48% vs. 63%) and a shorter time to progression than patients who received FAC versus placebo.<br/> In the clinical trials, patients who were initially randomized to receive placebo were allowed to receive dexrazoxane after a cumulative dose of doxorubicin above 300 mg/m<sup>2</sup>. Retrospective historical analyses showed that the risk of experiencing a cardiac event (see Table 3 for definition) at a cumulative dose of doxorubicin above 300 mg/m<sup>2</sup> was greater in the patients who did not receive dexrazoxane beginning with their seventh course of FAC than in the patients who did receive dexrazoxane (HR=13.08; 95% CI: 3.72, 46.03; p&lt;0.001). Overall, 3% of patients treated with dexrazoxane developed CHF compared with 22% of patients not receiving dexrazoxane.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 3: Definition of Cardiac Events:</content>
                  </paragraph>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Development of congestive heart failure, defined as having two or more of the following:<br/>     a. Cardiomegaly by X-ray<br/>     b. Basilar Rales<br/>     c. S3 Gallop<br/>     d. Paroxysmal nocturnal dyspnea and/or orthopnea and/or significant dyspnea on exertion.</item>
                     <item>Decline from baseline in LVEF by ≥10% and to below the lower limit of normal for the institution.</item>
                     <item>Decline in LVEF by ≥20% from baseline value.</item>
                     <item>Decline in LVEF to ≥5% below lower limit of normal for the institution.</item>
                  </list>
                  <paragraph>Figure 1 shows the number of patients still on treatment at increasing cumulative doses.<br/>
                     <content styleCode="bold">Figure 1<br/> Cumulative Number of Patients On Treatment FAC vs. FAC/Dexrazoxane Patients<br/> Patients Receiving at Least Seven Courses of Treatment</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20250409"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>dexra-inj-fig-01</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dexra-inj-fig-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_15">
               <id root="52d0b3e0-c73f-47d9-99b1-5362d0c023cb"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. “OSHA Hazardous Drugs.” OSHA http://www.osha.gov/SLTC/hazardousdrugs/index.html.</paragraph>
               </text>
               <effectiveTime value="20250409"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="1b617dac-5eef-4f79-a645-bb6bd6e2fd4a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <sup/>Dexrazoxane for injection is available in the following strengths as a sterile, off white to pale yellow pyrogen-free lyophilized powder in a single-dose vials for reconstitution.</paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="100%">
                     <colgroup>
                        <col width="33.32%"/>
                        <col width="33.34%"/>
                        <col width="33.34%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="top"> <content styleCode="bold">Strength</content>
                              <br/> </td>
                           <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">Pack Style</content>
                              <br/> </td>
                           <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">NDC Code</content>
                              <br/> </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="top"> 250 mg <br/> </td>
                           <td styleCode="Rrule" align="center" valign="top"> Carton of single-dose vial with a blue flip-top seal<br/> </td>
                           <td styleCode="Rrule" align="center" valign="top"> 72205-247-01<br/> </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="center" valign="top"> 500 mg <br/> </td>
                           <td styleCode="Rrule" align="center" valign="top"> Carton of single-dose vial with a blue flip-top seal<br/> </td>
                           <td styleCode="Rrule" align="center" valign="top"> 72205-248-01<br/> </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].<br/> Follow special handling and disposal procedures.<sup>1</sup>
                     <br/> Discard unused solutions.</paragraph>
               </text>
               <effectiveTime value="20250409"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="50c23450-19ba-40d3-9a0a-0aa4b0d2f062"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250409"/>
               <component>
                  <section ID="Section_16.2">
                     <id root="a54f2a5d-806c-465e-b19f-a4ca4bf1a81b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.1	Myelosuppression</title>
                     <text>
                        <paragraph>Treatment with dexrazoxane is associated with leukopenia, neutropenia, and thrombocytopenia. Perform hematological monitoring <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>, (5.6)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.3">
                     <id root="0fdf2c27-a40f-480a-8c06-56de36ec2a55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.2	Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Counsel patients on pregnancy planning and prevention. Advise female patients of reproductive potential that dexrazoxane can cause fetal harm and to use highly effective contraception during treatment <content styleCode="italics">[see <linkHtml href="#Section_5.5">Warnings and Precautions (5.5</linkHtml>) and <linkHtml href="#Section_8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#Section_8.6">8.6</linkHtml>)].</content>
                           <br/> This product’s label may have been updated. For current full prescribing information, please visit www.msnlabs.com.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Manufactured by:<br/> MSN Laboratories Private Limited</content>
                           <br/> Telangana – 509 228, INDIA</paragraph>
                        <paragraph>
                           <content styleCode="bold">Distributed by:<br/> Novadoz Pharmaceuticals LLC</content>
                           <br/> Piscataway, NJ 08854-3714<br/>
                           <content styleCode="bold">Issued on: 04/2023</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250409"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="bddadba6-c28e-406a-9194-840aaeb65032"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">250 mg/Vial Carton Label</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">250 mg/Vial Vial Label</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">500 mg/Vial Carton Label</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">500 mg/Vial Vial Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM6"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250409"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>dexra-inj-250mg-crtn-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dexra-inj-250mg-crtn-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>dexra-inj-250mg-cntr-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dexra-inj-250mg-cntr-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>dexra-inj-500mg-crtn-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dexra-inj-500mg-crtn-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>dexra-inj-500mg-cntr-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dexra-inj-500mg-cntr-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>